Literature DB >> 11891531

Axin, the main component of the Wnt signaling pathway, is not mutated in kidney tumors in children.

Jiangyong Miao1, Takeshi Kusafuka, Yuko Udatsu, Akira Okada.   

Abstract

The Wnt signaling pathway is essential for embryonic development and can be involved in tumorigenesis when aberrantly activated. In a subset of Wilms' tumors, beta-catenin mutations have been identified, and this suggested that abnormally activated Wnt signaling may contribute to tumorigenesis of this tumor. Because Axin has been recognized as a main component of Wnt signaling, and its mutations were reported in several types of malignancies, we analyzed Axin gene mutations in 22 pediatric renal tumors. Twenty-four sets of the primers, which cover the whole coding region of the Axin gene, were used for PCR-SSCP analyses. Samples revealing aberrant band patterns were further analyzed for sequencing. We have only identified 4 silent mutations in the coding region and 3 intronic polymorphisms in Axin gene, accordingly no pathogenetic gene mutations were detected. Our results indicated that mutations of Axin gene as a mechanism of tumorigenesis are not associated with pediatric renal tumors including Wilms' tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891531

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  2 in total

1.  Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear beta-catenin expression.

Authors:  L B Koppert; A W van der Velden; M van de Wetering; M Abbou; A M W van den Ouweland; H W Tilanus; B P L Wijnhoven; W N M Dinjens
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

2.  Reduced expression of Axin correlates with tumour progression of oesophageal squamous cell carcinoma.

Authors:  M Nakajima; M Fukuchi; T Miyazaki; N Masuda; H Kato; H Kuwano
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.